Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial.

Autor: Bar-Or A; Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. amitbar@pennmedicine.upenn.edu., Montalban X; Department of Neurology-Neuroimmunology and Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain., Hu X; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Kropshofer H; Novartis Pharma AG, Basel, Switzerland., Kukkaro P; Novartis Pharma AG, Basel, Switzerland., Coello N; Novartis Pharma AG, Basel, Switzerland., Ludwig I; Novartis Pharma AG, Basel, Switzerland., Willi R; Novartis Pharma AG, Basel, Switzerland., Zalesak M; Novartis Pharma AG, Basel, Switzerland., Ramanathan K; Novartis Pharma AG, Basel, Switzerland., Kieseier BC; Novartis Pharma AG, Basel, Switzerland.; Department of Neurology, Medical Faculty, Heinrich-Heine University, Dusseldorf, Germany., Häring DA; Novartis Pharma AG, Basel, Switzerland., Bagger M; Novartis Pharma AG, Basel, Switzerland., Fox E; Central Texas Neurology Consultants and Dell Medical School, The University of Texas at Austin, Round Rock, Austin, TX, USA.

Publikováno v: Neurology and therapy [Neurol Ther] 2023 Feb; Vol. 12 (1), pp. 303-317. Date of Electronic Publication: 2022 Dec 19.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Safe reopening of university campuses is possible with COVID-19 vaccination.

Autor: Junge M; Department of Mathematics, Baruch College, New York, New York, United States of America., Li S; School of Public Health, City University of New York, New York, New York, United States of America., Samaranayake S; School of Civil and Environmental Engineering, Cornell University, Ithaca, New York, United States of America., Zalesak M; School of Operations Research and Information Engineering, Cornell University, Ithaca, New York, United States of America.

Publikováno v: PloS one [PLoS One] 2022 Jul 21; Vol. 17 (7), pp. e0270106. Date of Electronic Publication: 2022 Jul 21 (Print Publication: 2022).

Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.

Autor: Bar-Or A; A Bar-Or Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, 3400 Spruce Street - 3 Gates Building, Philadelphia, PA 19104, USA.; Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Wiendl H; Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany., Montalban X; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain., Alvarez E; Department of Neurology, Rocky Mountain MS Center, University of Colorado, Aurora, CO, USA., Davydovskaya M; Pirogov Russian National Research Medical University, Moscow, Russian Federation., Delgado SR; MS Center and Department of Neurology, Miller School of Medicine, University of Miami, Miami, FL, USA., Evdoshenko EP; St Petersburg Center for Multiple Sclerosis and Other Autoimmune Diseases, St Petersburg, Russian Federation., Giedraitiene N; Clinic of Neurology and Neurosurgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania., Gross-Paju K; West-Tallinn Central Hospital, Tallinn, Estonia/Institute of Health Care Technology, TalTech, Tallinn, Estonia., Haldre S; Department of Neurology and Neurosurgery, University of Tartu, Tartu, Estonia/Neurology Clinic, Tartu University Hospital, Tartu, Estonia., Herrman CE; JWM Neurology, Indianapolis, IN, USA., Izquierdo G; Multiple Sclerosis Unit, Hospital Vithas NISA Sevilla, Sevilla, Spain., Karelis G; Neurology and Neurosurgery Department, Riga East University Hospital and Riga Stradins University, Riga, Latvia., Leutmezer F; Department of Neurology, Medical University of Vienna, Vienna, Austria., Mares M; Department of Neurology, Pardubice Regional Hospital, Pardubice, Czech Republic., Meca-Lallana JE; Multiple Sclerosis CSUR, Department of Neurology, Virgen de la Arrixaca Clinical University Hospital-IMIB-Arrixaca, Murcia, Spain/Clinical Neuroimmunology and Multiple Sclerosis Cathedra, Universidad Católica San Antonio (UCAM), Murcia, Spain., Mickeviciene D; Lithuanian University of Health Sciences, Kaunas, Lithuania., Nicholas J; OhioHealth Riverside Methodist Hospital, Columbus, OH, USA., Robertson DS; Multiple Sclerosis Division, Department of Neurology, Morsani College of Medicine, University of South Florida, Tampa, FL, USA., Sazonov DV; Department of Clinical Trials FSBIH SDMC of FMBA of Russia, Novosibirsk, Russian Federation., Sharlin K; Sharlin Health and Neurology, Ozark, MO, USA., Sundaram B; Texas Institute for Neurological Disorders, Sherman, TX, USA., Totolyan N; Department of Neurology, First Pavlov State Medical University of St Petersburg, St Petersburg, Russian Federation., Vachova M; Department of Neurology, Teplice Hospital, Teplice, Czech Republic., Valis M; Department of Neurology, Faculty of Medicine in Hradec Králové, Charles University in Prague and University Hospital Hradec Králové, Hradec Králové, Czech Republic., Bagger M; Novartis Pharma AG, Basel, Switzerland., Häring DA; Novartis Pharma AG, Basel, Switzerland., Ludwig I; Novartis Pharma AG, Basel, Switzerland., Willi R; Novartis Pharma AG, Basel, Switzerland., Zalesak M; Novartis Pharma AG, Basel, Switzerland., Su W; Novartis Pharmaceutical Corporation, East Hanover, NJ, USA., Merschhemke M; Novartis Pharma AG, Basel, Switzerland., Fox EJ; Central Texas Neurology Consultants PA, Round Rock, TX, USA.

Publikováno v: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2022 May; Vol. 28 (6), pp. 910-924. Date of Electronic Publication: 2021 Oct 04.